“…Since hostdependent proteolytic activation of virus infectivity is a universal mechanism in infection induced by influenza viruses (Klenk et al, 1975;Lazarowitz & Choppin, 1975;Bosch et al, 1979;Sugawara et al, 1981) and paramyxoviruses (Homma & Ohuchi, 1973 ;Scheid & Choppin, 1974;Nagai et al, 1976;Nagai & Klenk, 1977), protease inhibitors may be used for treatment of infection induced by most myxoviruses. Moreover, this approach may be valuable in therapy of a wide spectrum of viral diseases because many other viruses, including poxviruses (Ichihashi & Oie, 1982), reoviruses (Wallis et al, 1966;Rubin & Fields, 1980), retroviruses (Chang & Friedman, 1977;Pitha et al, 1978;Van der Hoorn et aI., 1983), rotaviruses (Estes et al, 1981) and coronaviruses (Otsuki & Tsubokura, 1981;Stroz et al, 1981), require proteolytic activation for their replication and pathogenicity. Thus, antiprotease compounds seem to be potential universal antiviral drugs.…”